Loading

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support

PeerCurrent

PcPeerCurrent

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Set your cadence Alerts Settings Help

Back to follows

Disease

Metastatic HER2 Negative Breast Carcinoma

1 development in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs Trials1 Reviews Guidelines

Latest

Everything in the corpus, newest first.

AUG 18, 2026 · PHASE 1 TRIAL

Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer

ClinicalTrials.gov

Phase 1 trial of a three-drug combination in metastatic breast cancer with dose-limiting toxicity as the primary endpoint; no results posted in this registry record.

PreliminaryNational Cancer Institute (NCI)Metastatic Breast Carcinoma Biopsy Procedure

Reported

PhasePhase 1

Planned enrollment24

Primary outcome measureDose-limiting Toxicity (DLT), up to 28 days…

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support